lgndz: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net income	79,669	-
Change in estimated fair value of contingent liabilities	-1,475	-
Depreciation of fixed assets and amortization of intangible assets	25,561	-
Accretion of short-term investments	2,943	-
Amortization of debt discount and issuance fees	708	-
Non-cash income from financial royalty assets	1,248	-
Cecl adjustment to financial royalty assets	-724	-
Impairment loss of financial royalty assets	0	-
Gain on pelthos transaction	53,072	-
Loss on derivative instruments	-134	-
Loss from equity method investment in primrose bio	0	-
(gain) loss from change in fair value of equity-method investments and other investments	75,887	-
Share-based compensation	32,579	-
Deferred income taxes, net	-12,113	-
Loss (gain) from short-term investments	-3,630	-
Lease amortization expense	1,462	-
Other	1,941	-
Accounts receivable	19,650	-
Inventory	-2,214	-
Accounts payable and accrued liabilities	-1,463	-
Income tax receivable and payable	-3,622	-
Deferred revenue	-578	-
Other assets and liabilities	6,099	-
Net cash provided by operating activities	3,444	-
Acquisition of financial royalty assets	10,212	-
Payments to acquire royalty receivables	813	-
Proceeds from financial royalty assets	8,766	-
Purchases of derivatives	8,679	-
Purchases of property and equipment	443	-
Purchases of short-term investments	514,856	-
Proceeds from sale of short-term investments	38,599	-
Proceeds from maturity of short-term investments	136,505	-
Cash outflow on pelthos transaction	8,085	-
Cash paid for investment in primrose bio	0	-
Cash paid for palvella notes receivable	0	-
Cash paid for the agenus transaction	0	-
Cash paid for apeiron acquisition, net of cash received	0	-
Cash paid for invios investment	0	-
Net cash used in investing activities	-359,218	-
Gross proceeds from issuance of 2030 convertible senior notes	460,000	-
Debt discount and payment of debt issuance cost	14,911	-
Purchase of 2030 convertible senior notes hedge	113,250	-
Proceeds from issuance of warrants	67,390	-
Repurchase of common stock	15,000	-
Proceeds from common stock issuance, net of commissions and fees	0	-
Payments under finance lease obligations	20	-
Payments to cvr holders	174	-
Net proceeds from stock option exercises and espp	38,203	-
Taxes paid related to net share settlement of equity awards	9,255	-
Proceeds from pelthos investors	6,910	-
Net decrease in cash and cash equivalents, including cash and cash equivalents classified within assets held for sale	-	-1,821
Net cash provided by financing activities	419,893	-
Less net increase in cash and cash equivalents classified within assets held for sale	-	-2,817
Effect of exchange rate changes on cash and cash equivalents	2,950	-
Net increase in cash and cash equivalents	67,069	-4,638
Cash and cash equivalents at beginning of period	72,307	-
Cash and cash equivalents at end of period	139,376	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

lgndz: the cashflow